Cullinan (NASDAQ: CGEM) starts zipalertinib NDA with up to $100 million

What happened

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) said on October 1, 2026, that it started an NDA submission for zipalertinib with platinum-based chemotherapy. The filing covers previously untreated, locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations under FDA Real-Time Oncology Review. RTOR lets sponsors submit clinical data before the full application so the FDA can review efficacy and safety sooner.

Cullinan expects to complete the NDA submission by year-end 2026. The filing relies on Phase 3 REZILIENT3 data, which met its primary endpoint and showed a statistically significant and clinically meaningful improvement in median progression-free survival versus chemotherapy alone. The company said the results were recently presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer during a Presidential Symposium. Zipalertinib is investigational and has not been approved by any health authority.

Key numbers

Metric	Latest	Change	Source
Milestone payment on U.S. approval in the second-line setting	$30.0 million		SEC 8-K
Milestone payment on U.S. approval in the first-line setting	up to $100.0 million		SEC 8-K
NDA submission completion expected	year-end 2026		Press release
PDUFA target action date for the monotherapy NDA	February 27, 2027		SEC 8-K

Read more: Cullinan Therapeutics (CGEM) stock analysis and investment case

Why it matters

OptimistFi's case is that Cullinan needs regulatory progress and future approval cash to support an event-driven stock. This filing helps that case by moving zipalertinib into the NDA process and tying milestone cash to approval. Cullinan is eligible for $30.0 million on U.S. approval in the second-line setting and up to $100.0 million on first-line approval.

The first-line amount is 3.33x the second-line payment, so more value sits behind first-line approval. Both payments still depend on future U.S. regulatory approval, and the larger amount is capped at $100.0 million. The filing also says zipalertinib has FDA Breakthrough Therapy designation for patients who previously received platinum-based chemotherapy.

Browse: stock research on every company OptimistFi covers

What's next

Cullinan expects to finish the current NDA submission by year-end 2026. If it hits that timeline, investors get a clearer read on the application path. A delay would push the regulatory clock back.

The separate monotherapy NDA remains under FDA review, with a PDUFA target action date of February 27, 2027. That is the next dated catalyst in the filing. A favorable FDA decision would support the milestone path, while a setback would slow it.

More from OptimistFi